UCI: Adverse Analytical Finding for Remy di Gregorio
Apr 11 2018 05:26 pm CET

UCI: Adverse Analytical Finding for Remy di Gregorio
UCI: Adverse Analytical Finding for Remy di Gregorio
UCI logo

Cycling's global governing body UCI has announced that French rider Remy di Gregorio of Delko-Marseille Provence-KTM was notified of an Adverse Analytical Finding of darbepoetin.

The sample was collected on March 8 of 2018, when the rider was participating in Paris-Nice.

Darbepoetin (dEPO) falls under "Peptide Hormones, Growth Factors, Related Substances and Mimetics", as the UCI explains.

"This intelligence-led doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling, with the collaboration of the Agence Française de Lutte contre le Dopage (AFLD) and the Office central de lutte contre les atteintes à l’environnement et à la santé publique (OCLAESP)," the UCI statement read.

Di Gregorio has the right to request the analysis of a B sample and has been provisionally suspended until the conclusion of the case.

The Frenchman finished 22nd in the overall classification of Paris-Nice. A month earlier, he won a stage in the Tour la Provence, his first win (excluding mountain classifications) on the European Tour since 2013.


Join our team!

Have you always wanted to write about cycling? Click HERE to contact us!
Get the latest cycling news in your mailbox

Enter your email address: